• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor
    Hero Background

    Arterial Stents Market

    ID: MRFR/HC/36527-HCR
    128 Pages
    Rahul Gotadki
    October 2025

    Arterial Stents Market Research Report By Type (Bare Metal Stents, Drug-Eluting Stents, Bioabsorbable Stents), By Application (Coronary Artery Disease, Peripheral Artery Disease, Neurovascular Disease), By Material (Metallic Stents, Polymer Stents, Combination Stents), By End Use (Hospitals, Ambulatory Surgical Centers, Specialized Clinics) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Arterial Stents Market Infographic
    Purchase Options

    Arterial Stents Market Summary

    As per MRFR analysis, the Arterial Stents Market Size was estimated at 4.795 USD Billion in 2024. The Arterial Stents industry is projected to grow from 5.007 USD Billion in 2025 to 7.726 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 4.43 during the forecast period 2025 - 2035.

    Key Market Trends & Highlights

    The Arterial Stents Market is experiencing robust growth driven by technological advancements and increasing healthcare demands.

    • Technological advancements in stent design are enhancing patient outcomes and procedural efficiency.
    • North America remains the largest market, while Asia-Pacific is emerging as the fastest-growing region for arterial stents.
    • Drug-eluting stents dominate the market, whereas bioabsorbable stents are witnessing rapid growth due to their innovative features.
    • The increasing prevalence of cardiovascular diseases and rising healthcare expenditure are key drivers propelling market expansion.

    Market Size & Forecast

    2024 Market Size 4.795 (USD Billion)
    2035 Market Size 7.726 (USD Billion)
    CAGR (2025 - 2035) 4.43%

    Major Players

    Medtronic (US), Boston Scientific (US), Abbott Laboratories (US), B. Braun Melsungen AG (DE), Terumo Corporation (JP), Cordis Corporation (US), Cook Medical (US), Johnson & Johnson (US), Stryker Corporation (US)

    Arterial Stents Market Trends

    The Arterial Stents Market is currently experiencing a transformative phase, driven by advancements in technology and an increasing prevalence of cardiovascular diseases. The demand for minimally invasive procedures has surged, leading to a greater adoption of stenting solutions. Innovations in materials and design are enhancing the efficacy and safety of these devices, which appears to be a crucial factor in their growing acceptance among healthcare professionals. Furthermore, the rising awareness regarding heart health and preventive measures is likely to contribute to the expansion of this market. As healthcare systems evolve, the integration of digital health solutions and telemedicine is also influencing the way arterial stents are utilized and monitored post-procedure. In addition, regulatory bodies are playing a pivotal role in shaping the landscape of the Arterial Stents Market. Stricter guidelines and approval processes may ensure that only the most effective and safe products reach the market. This could lead to a consolidation of manufacturers, as smaller companies may struggle to meet these requirements. Moreover, the increasing focus on patient-centric care is prompting manufacturers to develop stents that cater to specific patient needs, potentially enhancing patient outcomes. Overall, the Arterial Stents Market appears poised for growth, with a combination of technological advancements, regulatory influences, and evolving patient expectations driving its trajectory.

    Technological Advancements

    Recent innovations in stent design and materials are enhancing the performance and safety of arterial stents. Newer models are being developed with bioresorbable materials, which may reduce long-term complications and improve patient outcomes. Additionally, advancements in imaging technologies are facilitating better placement and monitoring of stents, potentially leading to more successful interventions.

    Regulatory Changes

    The evolving regulatory landscape is influencing the Arterial Stents Market significantly. Stricter approval processes and guidelines are being implemented to ensure the safety and efficacy of stenting devices. This trend may lead to a more competitive environment, as manufacturers strive to meet these standards while also innovating their product offerings.

    Patient-Centric Approaches

    There is a growing emphasis on patient-centric care within the healthcare sector, which is impacting the development of arterial stents. Manufacturers are increasingly focusing on creating devices that address specific patient needs and preferences. This trend may enhance patient satisfaction and improve overall treatment outcomes.

    The ongoing advancements in biocompatible materials and innovative designs in arterial stents appear to enhance patient outcomes and expand treatment options for cardiovascular diseases.

    U.S. Food and Drug Administration (FDA)

    Arterial Stents Market Drivers

    Rising Healthcare Expenditure

    The increase in healthcare expenditure across various regions is a significant driver for the Arterial Stents Market. As governments and private sectors allocate more resources to healthcare, the availability of advanced medical technologies, including arterial stents, improves. This trend is particularly evident in emerging economies, where rising disposable incomes and a growing middle class are leading to increased spending on healthcare services. The Arterial Stents Market stands to benefit from this trend, as more patients gain access to necessary fibromyalgia treatments. Furthermore, the emphasis on preventive care and early intervention in cardiovascular diseases is likely to drive demand for stenting procedures, thereby fostering market growth. The correlation between healthcare investment and the adoption of innovative medical devices is expected to remain strong.

    Aging Population and Lifestyle Changes

    The aging population and changing lifestyles are pivotal factors driving the Arterial Stents Market. As life expectancy increases, the prevalence of age-related cardiovascular conditions rises, necessitating effective treatment options such as arterial stents. Additionally, lifestyle changes, including poor dietary habits and sedentary behavior, contribute to the growing incidence of heart diseases. This demographic shift is prompting healthcare providers to seek advanced solutions to manage cardiovascular health. The Arterial Stents Market is likely to expand as healthcare systems adapt to these demographic trends, focusing on innovative stenting solutions that cater to the needs of older patients. The interplay between aging populations and lifestyle-related health issues is expected to create a sustained demand for arterial stents.

    Technological Innovations in Stent Design

    Technological advancements in stent design and materials are significantly influencing the Arterial Stents Market. Innovations such as drug-eluting stents and bioresorbable stents are enhancing the efficacy and safety of procedures. These advancements not only improve patient outcomes but also reduce the risk of complications, which is crucial in the treatment of cardiovascular diseases. The introduction of advanced imaging techniques and minimally invasive procedures has further propelled the market, allowing for more precise placements and better patient experiences. As the industry continues to evolve, the integration of smart technologies, such as sensors and drug delivery systems, is anticipated to revolutionize the Arterial Stents Market, potentially leading to increased adoption rates among healthcare providers.

    Regulatory Support and Reimbursement Policies

    Regulatory support and favorable reimbursement policies are crucial drivers for the Arterial Stents Market. Governments and health authorities are increasingly recognizing the importance of cardiovascular health, leading to the establishment of guidelines that promote the use of arterial stents. These regulations often facilitate quicker approvals for new stent technologies, encouraging innovation within the industry. Additionally, favorable reimbursement policies enhance patient access to stenting procedures, thereby driving market growth. As healthcare systems evolve, the alignment of regulatory frameworks with technological advancements is likely to bolster the Arterial Stents Market. The ongoing collaboration between regulatory bodies and industry stakeholders is expected to create a conducive environment for the development and adoption of new stenting solutions.

    Increasing Prevalence of Cardiovascular Diseases

    The rising incidence of cardiovascular diseases is a primary driver for the Arterial Stents Market. As populations age and lifestyle-related health issues become more prevalent, the demand for effective treatment options escalates. According to recent data, cardiovascular diseases account for a substantial percentage of global mortality, necessitating interventions such as stenting. This trend is likely to continue, as healthcare systems increasingly prioritize cardiovascular health. The Arterial Stents Market is expected to expand in response to this growing need, with innovations in stent technology enhancing patient outcomes and driving market growth. Furthermore, the increasing awareness of heart health among patients is likely to contribute to the demand for arterial stents, as individuals seek preventive measures and treatments for existing conditions.

    Market Segment Insights

    By Type: Drug-Eluting Stents (Largest) vs. Bioabsorbable Stents (Fastest-Growing)

    The Arterial Stents Market is primarily divided into three key segments: Bare Metal Stents, Drug-Eluting Stents (DES), and Bioabsorbable Stents. Among these, Drug-Eluting Stents hold the largest market share due to their effectiveness in reducing restenosis rates and improved clinical outcomes compared to Bare Metal Stents. While Bare Metal Stents have traditionally been popular for their simplicity and cost-effectiveness, their market position is increasingly challenged by the innovation of Drug-Eluting and Bioabsorbable Stents. Growth trends within the Arterial Stents Market are heavily influenced by advancements in technology, increased prevalence of cardiovascular diseases, and a growing demand for minimally invasive surgical options. Drug-Eluting Stents continue to dominate due to their advanced design that minimizes the risk of blood vessel narrowing post-procedure. On the other hand, Bioabsorbable Stents are emerging as the fastest-growing segment driven by their potential to provide temporary support during healing while eventually dissolving, thereby reducing long-term complications associated with permanent implants.

    Drug-Eluting Stents (Dominant) vs. Bioabsorbable Stents (Emerging)

    Drug-Eluting Stents (DES) are considered the dominant choice in the arterial stents market, known for their unique ability to release medication that inhibits cell proliferation. This significantly lowers the chances of restenosis, making them a preferred option for patients at risk of artery re-narrowing. DES are widely utilized in various procedures and backed by extensive clinical research demonstrating their effectiveness and safety. In contrast, Bioabsorbable Stents represent an emerging segment that aims to address the limitations of permanent stents. These innovative stents gradually dissolve over time, leaving no foreign material in the arteries after they have healed. Their appeal lies in the potential for reduced complications and improved long-term outcomes, fueling increasing investment and interest from healthcare providers.

    By Application: Coronary Artery Disease (Largest) vs. Peripheral Artery Disease (Fastest-Growing)

    In the Arterial Stents Market, the application segment is primarily divided into three key areas: Coronary Artery Disease, Peripheral Artery Disease, and Neurovascular Disease. Among these, Coronary Artery Disease stands out as the largest segment, capturing a substantial share of the market. This segment's dominance is driven by the high prevalence of coronary conditions, necessitating effective stenting solutions. Meanwhile, the Peripheral Artery Disease segment is emerging as the fastest-growing area, indicating increasing awareness and detection rates, alongside advancements in stent technologies tailored for peripheral applications.

    Coronary Artery Disease (Dominant) vs. Peripheral Artery Disease (Emerging)

    Coronary Artery Disease (CAD) remains the dominant application in the Arterial Stents Market due to its high incidence rates and significant clinical need for intervention. Stents used in CAD procedures exhibit advanced designs to enhance compatibility with various coronary anatomies and improve patient outcomes. In contrast, Peripheral Artery Disease (PAD) represents an emerging segment that is gaining traction as healthcare providers recognize its growing prevalence and associated complications. Innovations in PAD stenting solutions aim to provide improved deliverability and durability, catering to a broader patient demographic, thus driving this segment's rapid growth.

    By Material: Metallic Stents (Largest) vs. Polymer Stents (Fastest-Growing)

    In the Arterial Stents Market, metallic stents hold the largest market share, dominating the landscape due to their established presence and reliability in clinical settings. They are widely adopted for their superior strength and excellent flexibility, making them suitable for various arterial requirements. Meanwhile, polymer stents are gradually gaining traction, catering to the increasing demand for biocompatible materials. This shift reflects a significant interest among clinicians for alternatives that reduce the risk of restenosis and improve patient outcomes.

    Stent Types: Metallic (Dominant) vs. Polymer (Emerging)

    Metallic stents are characterized by their robust design and long-standing efficacy in treating arterial blockages, making them the dominant choice among healthcare professionals. Their ability to withstand significant mechanical stresses while maintaining structural integrity positions them as a reliable solution for a variety of patients. On the other hand, polymer stents are emerging as a preferred option due to advancements in material science that allow for greater flexibility and reduced thrombogenic response. These innovations enhance the safety profile of stents, appealing to a growing segment of the market focused on patient-friendly solutions.

    By End Use: Hospitals (Largest) vs. Ambulatory Surgical Centers (Fastest-Growing)

    In the Arterial Stents Market, Hospitals represent the largest end-use segment, capturing the majority share due to their comprehensive resources, specialized equipment, and availability of skilled healthcare professionals. They offer a wide range of services, positioning them as a primary choice for patients requiring arterial interventions. Conversely, Ambulatory Surgical Centers are experiencing rapid growth, driven by the increasing preference for outpatient procedures, cost-effective solutions, and shorter recovery times, leading to a significant shift towards these facilities.

    Hospitals (Dominant) vs. Ambulatory Surgical Centers (Emerging)

    Hospitals dominate the arterial stents market due to their extensive healthcare infrastructure, specialized staff, and advanced technologies. These facilities are well-equipped to handle complex cases, offering a variety of arterial stenting procedures that cater to a broad patient demographic. In contrast, Ambulatory Surgical Centers are emerging as a popular alternative, primarily for elective procedures. They focus on outpatient care, promoting convenience and lower costs, which attract a growing patient base. This shift reflects a trend towards minimally invasive interventions and patient-centric care, positioning Ambulatory Surgical Centers as a significant player in the market.

    Get more detailed insights about Arterial Stents Market

    Regional Insights

    North America : Market Leader in Innovation

    North America is the largest market for arterial stents, accounting for approximately 45% of the global market share. The region's growth is driven by advanced healthcare infrastructure, increasing prevalence of cardiovascular diseases, and a strong focus on research and development. Regulatory support from agencies like the FDA further catalyzes innovation and market expansion, ensuring that new technologies are rapidly adopted. The United States is the primary contributor to this market, with key players such as Medtronic, Boston Scientific, and Abbott Laboratories leading the competitive landscape. The presence of these major companies fosters a robust environment for innovation and competition. Additionally, the growing aging population and rising healthcare expenditure are expected to sustain demand for arterial stents in the coming years.

    Europe : Emerging Regulatory Frameworks

    Europe is the second-largest market for arterial stents, holding around 30% of the global market share. The region's growth is propelled by increasing awareness of cardiovascular health, advancements in medical technology, and supportive regulatory frameworks. The European Medicines Agency (EMA) plays a crucial role in ensuring that new stent technologies meet safety and efficacy standards, which encourages innovation and market entry. Leading countries in this region include Germany, France, and the UK, where a strong healthcare system and high patient awareness contribute to market growth. Key players such as B. Braun Melsungen AG and Terumo Corporation are actively involved in expanding their product offerings. The competitive landscape is characterized by continuous innovation and strategic partnerships, enhancing the availability of advanced stent solutions.

    Asia-Pacific : Rapidly Growing Market Potential

    Asia-Pacific is witnessing rapid growth in the arterial stents market, accounting for approximately 20% of the global share. The region's expansion is fueled by increasing healthcare investments, rising prevalence of lifestyle-related diseases, and a growing middle-class population. Countries like China and India are at the forefront, with government initiatives aimed at improving healthcare access and affordability, which are critical for market growth. China is the largest market in this region, with significant contributions from local manufacturers and international players. The competitive landscape is evolving, with companies like Cordis Corporation and Cook Medical expanding their presence. The increasing focus on minimally invasive procedures and technological advancements in stent design are expected to drive further growth in the coming years.

    Middle East and Africa : Untapped Market Opportunities

    The Middle East and Africa region represents a smaller share of the arterial stents market, approximately 5%, but it is characterized by significant growth potential. The market is driven by increasing healthcare investments, rising awareness of cardiovascular diseases, and improving healthcare infrastructure. However, challenges such as economic disparities and varying regulatory environments can hinder market growth in certain areas. Countries like South Africa and the UAE are leading the market, with a growing number of healthcare facilities and increasing patient access to advanced medical technologies. Key players are beginning to explore opportunities in this region, focusing on partnerships and collaborations to enhance market penetration. The competitive landscape is gradually evolving as more companies recognize the potential of this emerging market.

    Key Players and Competitive Insights

    The Arterial Stents Market is characterized by a dynamic competitive landscape, driven by technological advancements, increasing prevalence of cardiovascular diseases, and a growing aging population. Major players such as Medtronic (US), Boston Scientific (US), and Abbott Laboratories (US) are at the forefront, each adopting distinct strategies to enhance their market presence. Medtronic (US) focuses on innovation through the development of next-generation stent technologies, while Boston Scientific (US) emphasizes strategic partnerships to expand its product portfolio. Abbott Laboratories (US) is leveraging its strong research capabilities to introduce advanced drug-eluting stents, thereby enhancing its competitive positioning. Collectively, these strategies contribute to a robust competitive environment, fostering continuous improvement and innovation within the market.

    Key business tactics employed by these companies include localizing manufacturing and optimizing supply chains to enhance operational efficiency. The Arterial Stents Market appears moderately fragmented, with a mix of established players and emerging companies. The collective influence of key players shapes market dynamics, as they compete not only on product quality but also on service delivery and technological advancements.

    In August 2025, Medtronic (US) announced the launch of its latest drug-eluting stent, which incorporates advanced bioresorbable technology aimed at reducing the risk of restenosis. This strategic move is significant as it positions Medtronic (US) to capture a larger share of the market by addressing the growing demand for innovative solutions that enhance patient outcomes. The introduction of this product is expected to strengthen Medtronic's (US) competitive edge in a rapidly evolving market.

    In September 2025, Boston Scientific (US) entered into a strategic partnership with a leading digital health company to integrate AI-driven analytics into its stent monitoring systems. This collaboration is indicative of a broader trend towards digitalization in the healthcare sector, suggesting that Boston Scientific (US) is keen on enhancing patient management and outcomes through technology. Such initiatives may not only improve operational efficiencies but also provide a competitive advantage in a market increasingly focused on data-driven solutions.

    In July 2025, Abbott Laboratories (US) expanded its manufacturing capabilities in Europe to meet the rising demand for its innovative stent products. This expansion reflects Abbott's (US) commitment to regional growth and supply chain optimization, which is crucial in maintaining a competitive edge. By enhancing its production capacity, Abbott (US) is likely to improve its responsiveness to market needs and strengthen its position against competitors.

    As of October 2025, current competitive trends in the Arterial Stents Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are becoming more prevalent, as companies recognize the importance of collaboration in driving innovation and enhancing product offerings. Looking ahead, competitive differentiation is expected to evolve, with a notable shift from price-based competition towards a focus on innovation, technological advancements, and supply chain reliability. This transition may redefine market dynamics, compelling companies to invest in research and development to stay ahead in a competitive landscape.

    Key Companies in the Arterial Stents Market market include

    Industry Developments

    • Q2 2024: Boston Scientific to acquire Silk Road Medical for $1.2 billion Boston Scientific announced a definitive agreement to acquire Silk Road Medical, a company specializing in transcarotid artery revascularization and stent systems, for $1.2 billion to expand its vascular intervention portfolio.
    • Q2 2024: FDA approves Medtronic's Onyx Frontier drug-eluting stent for U.S. market Medtronic received FDA approval for its Onyx Frontier drug-eluting stent, designed for the treatment of coronary artery disease, marking a significant regulatory milestone for the company's interventional cardiology business.
    • Q2 2024: Abbott Receives CE Mark for Navitor Transcatheter Aortic Valve Implantation System Abbott announced it has received CE Mark approval for its Navitor TAVI system, which includes a new arterial stent design for minimally invasive heart valve replacement procedures in Europe.
    • Q3 2024: Biotronik launches Pulsar-18 T3 peripheral self-expanding stent in the U.S. Biotronik announced the U.S. commercial launch of its Pulsar-18 T3 peripheral self-expanding stent, designed for the treatment of femoropopliteal arterial disease, expanding its vascular intervention product line.
    • Q3 2024: MicroPort Scientific Corporation receives NMPA approval for Firehawk Liberty drug-eluting stent in China MicroPort Scientific Corporation announced that its Firehawk Liberty drug-eluting stent has received regulatory approval from the National Medical Products Administration (NMPA) in China for the treatment of coronary artery disease.
    • Q3 2024: Cordis Announces FDA Clearance of SABERX Drug-Coated Balloon and Launch of New Stent Platform Cordis received FDA clearance for its SABERX drug-coated balloon and simultaneously launched a new peripheral arterial stent platform in the United States, enhancing its endovascular product offerings.
    • Q4 2024: Boston Scientific launches Synergy XD drug-eluting stent in Europe Boston Scientific announced the European launch of its Synergy XD drug-eluting stent, designed to improve deliverability and clinical outcomes for patients with coronary artery disease.
    • Q4 2024: Terumo receives FDA approval for Ultimaster Tansei drug-eluting stent Terumo announced it has received FDA approval for its Ultimaster Tansei drug-eluting stent, enabling the company to expand its presence in the U.S. coronary intervention market.
    • Q1 2025: Medtronic launches Resolute Onyx 2.0 mm drug-eluting stent in Japan Medtronic announced the commercial launch of its Resolute Onyx 2.0 mm drug-eluting stent in Japan, targeting the treatment of small vessel coronary artery disease.
    • Q1 2025: Biosensors International receives CE Mark for BioFreedom Ultra drug-coated stent Biosensors International announced it has received CE Mark approval for its BioFreedom Ultra drug-coated stent, allowing commercialization in the European Union for patients with coronary artery disease.
    • Q2 2025: Abbott to open new manufacturing facility for vascular devices in Ireland Abbott announced plans to open a new manufacturing facility in Ireland dedicated to the production of vascular devices, including arterial stents, to meet growing global demand.
    • Q2 2025: Boston Scientific appoints new president for Interventional Cardiology division Boston Scientific announced the appointment of a new president for its Interventional Cardiology division, responsible for overseeing the company's arterial stents and related product lines.

    The current affairs indicate a competitive market environment, with major players actively seeking to capture market share while adapting to evolving healthcare needs. The overall market valuation is witnessing an upward trajectory, driven by the rising prevalence of cardiovascular diseases, which further stimulates demand for advanced stent technologies. This fiscal trend underscores a healthy growth outlook for the Arterial Stents Market as leading firms continue to invest in research and development to enhance treatment options available to healthcare providers.

    Future Outlook

    Arterial Stents Market Future Outlook

    The Arterial Stents Market is projected to grow at a 4.43% CAGR from 2024 to 2035, driven by technological advancements, increasing cardiovascular diseases, and rising healthcare expenditures.

    New opportunities lie in:

    • Development of biodegradable stents for enhanced patient outcomes.
    • Expansion into emerging markets with tailored pricing strategies.
    • Integration of telemedicine for post-operative monitoring and support.

    By 2035, the Arterial Stents Market is expected to achieve substantial growth and innovation.

    Market Segmentation

    Arterial Stents Market Type Outlook

    • Bare Metal Stents
    • Drug-Eluting Stents
    • Bioabsorbable Stents

    Arterial Stents Market End Use Outlook

    • Hospitals
    • Ambulatory Surgical Centers
    • Specialized Clinics

    Arterial Stents Market Material Outlook

    • Metallic Stents
    • Polymer Stents
    • Combination Stents

    Arterial Stents Market Application Outlook

    • Coronary Artery Disease
    • Peripheral Artery Disease
    • Neurovascular Disease

    Report Scope

    MARKET SIZE 20244.795(USD Billion)
    MARKET SIZE 20255.007(USD Billion)
    MARKET SIZE 20357.726(USD Billion)
    COMPOUND ANNUAL GROWTH RATE (CAGR)4.43% (2024 - 2035)
    REPORT COVERAGERevenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR2024
    Market Forecast Period2025 - 2035
    Historical Data2019 - 2024
    Market Forecast UnitsUSD Billion
    Key Companies ProfiledMarket analysis in progress
    Segments CoveredMarket segmentation analysis in progress
    Key Market OpportunitiesAdvancements in biodegradable stent technology enhance patient outcomes in the Arterial Stents Market.
    Key Market DynamicsTechnological advancements and regulatory changes are reshaping competitive dynamics in the arterial stents market.
    Countries CoveredNorth America, Europe, APAC, South America, MEA

    Leave a Comment

    FAQs

    What is the projected market valuation of the Arterial Stents Market by 2035?

    The Arterial Stents Market is projected to reach a valuation of 7.726 USD Billion by 2035.

    What was the market valuation of the Arterial Stents Market in 2024?

    In 2024, the Arterial Stents Market was valued at 4.795 USD Billion.

    What is the expected CAGR for the Arterial Stents Market during the forecast period 2025 - 2035?

    The expected CAGR for the Arterial Stents Market during the forecast period 2025 - 2035 is 4.43%.

    Which type of stent segment had the highest valuation in 2024?

    In 2024, the Drug-Eluting Stents segment had the highest valuation at 2.5 USD Billion.

    What are the projected values for Bare Metal Stents by 2035?

    The projected value for Bare Metal Stents is expected to reach 2.4 USD Billion by 2035.

    Which application segment is anticipated to grow the most by 2035?

    The Coronary Artery Disease application segment is anticipated to grow the most, reaching 3.863 USD Billion by 2035.

    What is the expected market size for Polymer Stents by 2035?

    The expected market size for Polymer Stents is projected to be 1.93275 USD Billion by 2035.

    Who are the key players in the Arterial Stents Market?

    Key players in the Arterial Stents Market include Medtronic, Boston Scientific, and Abbott Laboratories, among others.

    What is the projected value for Neurovascular Disease application segment by 2035?

    The projected value for the Neurovascular Disease application segment is expected to be 1.554 USD Billion by 2035.

    What is the anticipated market size for hospitals as an end-use segment by 2035?

    The anticipated market size for hospitals as an end-use segment is projected to reach 3.863 USD Billion by 2035.

    Download Free Sample

    Kindly complete the form below to receive a free sample of this Report

    Case Study
    Chemicals and Materials

    Compare Licence

    ×
    Features License Type
    Single User Multiuser License Enterprise User
    Price $4,950 $5,950 $7,250
    Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
    Free Customization
    Direct Access to Analyst
    Deliverable Format
    Platform Access
    Discount on Next Purchase 10% 15% 15%
    Printable Versions